Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Study Treatment (SVR4)

SVR4 was defined as HCV RNA \< LLOQ 4 weeks after the last dose of study drug.

Time frame: Posttreatment Week 4

Percentage of Participants With HCV RNA < LLOQ on Treatment

Time frame: Weeks 2, 4, and 6

Change From Baseline in HCV RNA at Weeks 2, 4, and 6

Time frame: Baseline; Weeks 2, 4, and 6

Percentage of Participants With Virologic Failure

Virologic failure was defined as: * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), * HCV RNA persistently ≥ LLOQ through end of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement

Time frame: Up to Posttreatment Week 12

Change in HIV RNA From Day 1 to End of Treatment as Assessed by Proportion of Participants Who Had Confirmed HIV Virologic Rebound During the Study.